NCI’s publicly announced move to create an ad hoc working group that would review the feasibility and viability of the TMIST trial threatens to undercut this trial, said Mitchell Schnall, co-chair of ECOG-ACRIN Cancer Research Group, the group conducting the study.
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
